Paul Riska is an Infectious Disease physician affiliated with Albert Einstein College of Medicine. OpenAlex indexes 50 publications with 2,384 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
111 E 210th St
Bronx, NY 104672401
Telephone
718-920-6494Registry record last updated 26 Apr 2012.
Clinical trials
- Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
Sponsor: Montefiore Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20258 payments
- PFIZER INC.Program year20251 payment
- Gilead Sciences, Inc.Program year20245 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
21.3%Statin7.1%Atorvastatin Calcium75%Rosuvastatin Calcium14%Pravastatin Sodium11%Part D<11 patientsCalcium channel blocker3.4%Amlodipine Besylate59%Nifedipine Er27%Amlodipine Besylate-Benazepril13%Part D<11 patients+ 11 more classes in this area
Nervous system
20.7%Gabapentinoids4.9%Gabapentin63%Pregabalin37%Part D<11 patientsOpioid Agonist4.8%Oxycodone Hcl66%Oxycodone-Acetaminophen21%Methadone Hcl13%Part D<11 patients+ 10 more classes in this area
Anti-infectives
17.2%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor4.3%Tivicay35%Dovato35%Juluca13%Cabenuva11%Isentress Hd7%Part D<11 patientsProtease Inhibitor3.5%Prezcobix46%Symtuza45%Lopinavir-Ritonavir9%Part D<11 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1998–2002 per NIH RePORTER. The latest:
- MYCOBACTERIOPHANGE INTERACTION WITH M TUBERCULOSIS
Suny Downstate Medical Center
FY2002$126,900K08AI001628 - MYCOBACTERIOPHANGE INTERACTION WITH M TUBERCULOSIS
Suny Downstate Medical Center
FY2001$126,495K08AI001628 - MYCOBACTERIOPHANGE INTERACTION WITH M TUBERCULOSIS
Suny Downstate Medical Center
FY2000$126,090K08AI001628
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 214. Clinical Characteristics and Outcomes of Patients Treated with Tecovirimat for Mpox Disease: A Large Cohort in New York City
Open Forum Infectious Diseases
2025 - Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
Clinical Infectious Diseases
2025 - SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir
The Journal of Infectious Diseases
2024 - Use of Maribavir for Multidrug-Resistant Cytomegalovirus in an Immunocompromised Host With HIV and Common Variable Immunodeficiency
Annals of Internal Medicine Clinical Cases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Lipton, MD
Albert Einstein College of Medicine
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine
Solomon Moshe, MD
Albert Einstein College of Medicine
Shlomo Shinnar, MD, PhD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”